

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC AND
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC,
Petitioners,

v.

ALMIRALL, LLC,
Patent Owner.

Case IPR2019-00207
U.S. Patent No. 9,517,219

PETITIONERS' REPLY TO PATENT OWNER'S RESPONSE

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

INTRODUCTION 1

ARGUMENT 4

I. MOST OF ALMIRALL’S ARGUMENTS WERE ADVANCED IN THE RELATED ’926 PATENT IPR, NONE OF WHICH THE BOARD ACCEPTED IN ITS DECISION..... 4

II. ALMIRALL HAS NOT REBUTTED AMNEAL’S PRIMA FACIE CASE OF OBVIOUSNESS..... 5

A. Under *Dupont* and *Galderma*, Almirall’s lack-of-motivation arguments for the claimed dapsone and ethoxydiglycol percentages are legally irrelevant.....5

B. Actual artisans before 2012 selected dapsone for product development, confirming a POSA’s motivation.6

C. Garrett does not “teach away” or negate motivation to select dapsone.9

1. Garrett’s teachings are not limited to undissolved dapsone..... 9

2. Garrett (and other prior art) taught that dapsone “treats” acne and rosacea. 11

D. A POSA had reason to use 7.5% w/w dapsone.....13

E. Garrett and other art teach using topical dapsone compositions without adapalene.15

F. Garrett teaches using the claimed ethoxydiglycol amounts.....17

III. A POSA HAD REASON TO USE SEPINEO WITH GARRETT’S DAPSONE COMPOSITIONS. 19

A. Garrett is *not* incompatible with Nadau-Fourcade.....19

1. Compositions containing dissolved API would not have dissuaded a POSA. 19

2.	Carbopol® and Sepineo® are interchangeable.....	20
3.	The claimed A/SA range would have been obvious.....	22
B.	Garrett combined with Bonacucina renders the challenged claims obvious.....	23
1.	There were multiple reasons to combine Garrett with Bonacucina.....	23
2.	Bonacucina renders the claimed PVB amount obvious.....	24
IV.	SECONDARY CONSIDERATIONS CANNOT RESCUE THE '219 PATENT.....	24
1.	Compatibility of Sepineo® with 40% ethoxydiglycol was not unexpected.....	25
2.	The smaller particle size was not unexpected.....	25
3.	No others failed.....	27
	CONCLUSION.....	28

TABLE OF AUTHORITIES

Cases	Page(s)
<i>Allergan, Inc. v. Sandoz Inc.</i> , 726 F.3d 1286 (Fed. Cir. 2013)	12
<i>Almirall LLC v. Taro Pharm. Indus. LTD.</i> , C.A. No. 17-00663 (D. Del.), D.I. 87	20
<i>BTG Int’l Ltd. v. Amneal Pharm. LLC</i> , 923 F.3d 1063 (Fed. Cir. 2019)	8, 16
<i>Daiichi Sankyo Co., Ltd. v. Apotex, Inc.</i> , 501 F.3d 1254 (Fed. Cir. 2007)	21
<i>Duramed Pharm., Inc. v. Watson Labs., Inc.</i> , 413 F. App’x 289 (Fed. Cir. 2011)	12
<i>E.I. DuPont de Nemours & Co. v. Synvina C.V.</i> , 904 F.3d 996 (Fed. Cir. 2018)	6
<i>Galderma Labs., L.P. v. Tolmar, Inc.</i> , 737 F.3d 731 (Fed. Cir. 2013)	5, 6, 27
<i>Healthcare Inc. v. Daiichi Sankyo Co., Ltd.</i> , IPR2015-00865, Paper 104, 17 (Sept. 12, 2016).....	14
<i>Interactive Pictures Corp. v. Infinite Pictures, Inc.</i> , 274 F.3d 1371 (Fed, Cir. 2001)	22
<i>In re Mouttet</i> , 686 F.3d 1322 (Fed. Cir. 2012)	7
<i>Ormco Corp. v. Align Technology, Inc.</i> , 463 F.3d 1299 (Fed. Cir. 2006)	28
<i>SightSound Techs., LLC v. Apple Inc.</i> , 809 F.3d 1307 (Fed. Cir. 2015)	10
<i>Süd-Chemie, Inc. v. Multisorb Techs., Inc.</i> , 554 F.3d 1001 (Fed. Cir. 2009)	17

Case IPR2019-00207

Patent No. 9,517,219

Upsher-Smith Labs., Inc. v. Pamlab, LLC,

412 F.3d 1319 (Fed. Cir. 2005)16

Wm. Wrigley Jr. Co. v. Cadbury Adams USA LLC,

683 F.3d 1356 (Fed. Cir. 2012)21

Wockhardt Bio AG v. Janssen Oncology, Inc.,

IPR2016-01582, Paper 72, 22 (PTAB Jan. 17, 2018)14

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.